Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...

A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the ...

As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...

Which genes are required for turning embryonic stem cells into brain cells, and what happens when this process goes wrong? In ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

A sweeping genetic screen reveals how the brain is built and exposes a hidden gene behind a newly discovered childhood brain ...

By editing thousands of genes in mouse stem cells, the scientists identified a list of over 300 that are crucial for neural differentiation.

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $90 from $93 and keeps a Buy rating on the shares.

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...